Browse Studies — Arctuva

Phase 1

PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High-Grade Gliomas

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have co…

Recurrent World Health Organization (WHO) Grade II GliomaLow-grade GliomaHigh-Grade Glioma (HGG)

Estimated

~$10 – $5,625

University of California, San FranciscoNCT04485559

Phase 2

A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) loc…

Cancer Harboring BRAF AlterationsHGGLGG+1 more

Estimated

~$10 – $8,750

Fore BiotherapeuticsNCT05503797

Phase 2

A Randomized Trial of Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. Th…

High-grade Gliomas (HGG)

Estimated

~$10 – $7,500

Akshitkumar MIstryNCT07694089

Phase 1

Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown…

Brain CancerHGGGlioma+4 more

Estimated

~$10 – $7,500

Eben RosenthalNCT07210632